Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Theravance Biopharma (NASDAQ:TBPH) from a "buy" to a "strong-buy" rating in a research note issued Tuesday.
• Analyst opinions are mixed—two Strong Buy, two Buy and four Hold—leaving a MarketBeat consensus of "Moderate Buy" with a consensus target price of $21.83.
• Insider SVP Rhonda Farnum sold 31,067 shares on March 16 at about $13.96 (reducing her stake ~11.8%); TBPH trades near $16.50, has a market cap of ~$849.6M, a 52-week range of $8.31–$21.03, and a P/E of 8.13.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Tuesday.

Several other analysts also recently commented on the company. Weiss Ratings downgraded Theravance Biopharma from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday. BTIG Research reissued a "buy" rating and issued a $21.00 price objective on shares of Theravance Biopharma in a research note on Friday, March 20th. Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Thursday, March 19th. HC Wainwright increased their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Finally, B. Riley Financial increased their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Theravance Biopharma has a consensus rating of "Moderate Buy" and a consensus target price of $21.83.

Theravance Biopharma Stock Performance

TBPH stock opened at $16.50 on Tuesday. The stock's 50 day simple moving average is $16.69 and its 200 day simple moving average is $17.09. Theravance Biopharma has a fifty-two week low of $8.31 and a fifty-two week high of $21.03. The company has a market cap of $849.63 million, a P/E ratio of 8.13 and a beta of 0.17.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares of the company's stock, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors have recently modified their holdings of TBPH. Quarry LP bought a new position in shares of Theravance Biopharma in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock valued at $40,000 after acquiring an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company's stock valued at $46,000 after acquiring an additional 515 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 4,662 shares in the last quarter. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.